31P S-Vegf (Vascular Endothelial Growth Factor) as Predictive Factor in Response to Anthracycline Based Chemotherapy in Patients with Locally Advanced Breast Cancer

Growth Factor ◽

Advanced Breast Cancer ◽

Predictive Factor ◽

Locally Advanced ◽

Advanced Breast ◽

Vascular Endothelial ◽

Evaluation of Lymphangiogenic Factors, Vascular Endothelial Growth Factor D and E-Cadherin in Distinguishing Inflammatory From Locally Advanced Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.04.005 ◽

2012 ◽

Vol 12 (4) ◽

pp. 232-239 ◽

Cited By ~ 10

Author(s):

Paul H. Levine ◽

Chia C. Portera ◽

Heather J. Hoffman ◽

Sherry X. Yang ◽

Mikiko Takikita ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

E Cadherin

Expression of Vascular Endothelial Growth Factor and Proliferation Marker MIB1 Are Influenced by Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Applied Immunohistochemistry ◽

10.1097/01.pai.0000137364.36091.b0 ◽

2005 ◽

Vol 13 (2) ◽

pp. 147-156 ◽

Cited By ~ 6

Author(s):

Meenakshi Singh ◽

Kelly E Capocelli ◽

Jeni L Marks ◽

Rhoda B Schleicher ◽

Christina A Finlayson ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Advanced Breast Cancer ◽

Locally Advanced ◽

Vascular Endothelial ◽

Proliferation Marker ◽

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial Of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Yearbook of Oncology ◽

10.1016/s1040-1741(09)79334-0 ◽

2009 ◽

Vol 2009 ◽

pp. 11-12

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Advanced Breast Cancer ◽

Genetic Polymorphisms ◽

Growth Factor Receptor ◽

Advanced Breast ◽

Vascular Endothelial ◽

Race to Report: Are Vascular Endothelial Growth Factor Genetic Polymorphisms Associated With Outcome in Advanced Breast Cancer Patients Treated With Paclitaxel Plus Bevacizumab?

Journal of Clinical Oncology ◽

10.1200/jco.2008.20.6359 ◽

2009 ◽

Vol 27 (8) ◽

pp. 1342-1342 ◽

Cited By ~ 1

Author(s):

Tan Min-Han ◽

Tan Chuen Seng ◽

Lim Wei Yen

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Genetic Polymorphisms ◽

Advanced Breast ◽

Vascular Endothelial ◽

Breast Cancer Patients ◽

Faculty Opinions recommendation of Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1123035.580146 ◽

2008 ◽

Author(s):

Philippe Van Trappen

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Advanced Breast Cancer ◽

Genetic Polymorphisms ◽

Growth Factor Receptor ◽

Advanced Breast ◽

Vascular Endothelial ◽

Abstract P1-08-26: Hypertension and phosphorylated vascular endothelial growth factor receptor 2 are potential independent predictive factors for progession-free survival in apatinib-treated advanced breast cancer

10.1158/0008-5472.sabcs13-p1-08-26 ◽

2013 ◽

Author(s):

M Fan ◽

X Hu ◽

J Zhang ◽

Z Wang ◽

Q Zhang

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Advanced Breast Cancer ◽

Predictive Factors ◽

Growth Factor Receptor ◽

Advanced Breast ◽

Vascular Endothelial ◽

Free Survival ◽

Lymphopenia as a predictive factor of responsiveness to preoperative treatment in patients with locally advanced breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e21096 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e21096-e21096 ◽

Cited By ~ 1

Author(s):

C. R. Desposorio ◽

F. Hurtado de Mendoza ◽

S. G. Falcon ◽

A. R. Capellino ◽

R. Lujan ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Predictive Factor ◽

Locally Advanced ◽

Advanced Breast ◽

Preoperative Treatment

The role of Topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.032 ◽

2018 ◽

Vol 92 ◽

pp. S12-S13

Author(s):

M.M. Gamea

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Predictive Factor ◽

Topoisomerase Ii ◽

Locally Advanced ◽

Advanced Breast ◽

Topoisomerase Ii Α

The role of topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy314.025 ◽

2018 ◽

Vol 29 ◽

pp. vi28

Author(s):

M.M. Gamea

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Predictive Factor ◽

Topoisomerase Ii ◽

Locally Advanced ◽

Advanced Breast ◽

Topoisomerase Ii Α

The role of Topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(18)30559-8 ◽

2018 ◽

Vol 92 ◽

pp. S111

Author(s):

M. Gamea

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Predictive Factor ◽

Topoisomerase Ii ◽

Locally Advanced ◽

Advanced Breast ◽

Topoisomerase Ii Α